KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBITDA Margin (2020 - 2025)

Recursion Pharmaceuticals' EBITDA Margin history spans 6 years, with the latest figure at 304.84% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 373757.0% year-over-year to 304.84%; the TTM value through Dec 2025 reached 867.87%, down 7159.0%, while the annual FY2025 figure was 867.87%, 5377.0% down from the prior year.
  • EBITDA Margin reached 304.84% in Q4 2025 per RXRX's latest filing, up from 3327.57% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 304.84% in Q4 2025 to a low of 4042.41% in Q4 2024.
  • Average EBITDA Margin over 5 years is 1232.35%, with a median of 895.73% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: soared 2938181bps in 2021, then tumbled -313405bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 2564.55% in 2021, then skyrocketed by 83bps to 445.91% in 2022, then crashed by -104bps to 908.36% in 2023, then tumbled by -345bps to 4042.41% in 2024, then soared by 92bps to 304.84% in 2025.
  • Per Business Quant, the three most recent readings for RXRX's EBITDA Margin are 304.84% (Q4 2025), 3327.57% (Q3 2025), and 916.75% (Q2 2025).